Devyn Smith, Arbor Biotechnologies CEO
March 18, 2025 06:30 AM EDT
Financing
Startups
R&D

CRISPR com­pa­ny Ar­bor rais­es $73.9M to test ther­a­py in clin­i­cal tri­als

Ryan Cross

Senior Science Correspondent

Ar­bor Biotech­nolo­gies, a start­up found­ed by CRISPR pi­o­neer Feng Zhang nine years ago, has closed a $73.9 mil­lion Se­ries C fi­nanc­ing to bring its first …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Six­teen-year-old dies af­ter re­ceiv­ing Sarep­ta’s Duchenne gene ther­a­py

Up­dat­ed: No­var­tis re­vamps car­dio­vas­cu­lar com­mer­cial strat­e­gy as En­tresto patent cliff looms 

Stoke CEO Ed Kaye to de­part short­ly af­ter ink­ing Bio­gen pact and be­fore its first Phase 3 tri­al

Stem cell com­pa­ny bit.bio cuts quar­ter of staff, drops ther­a­peu­tics fo­cus

A Japan­ese biotech found­ed by Treg cell dis­cov­er­er moves to the US with $45.8M

Em­press Ther­a­peu­tics con­firms lay­offs; Nanobi­otix amends J&J deal terms

A service from the Financial Times